Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): Design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates

Journal of Medicinal Chemistry

Volumn 53, Issue 1, 2010, Pages 452-459

  Ayral Kaloustian, Semiramis ^a   Gu, Jianxin ^a   Lucas, Judy ^a   Cinque, Michael ^a   Gaydos, Christine ^a   Zask, Arie ^a   Chaudhary, Inder ^a   Wang, Jianyao ^a   Di, Li ^a   Young, Mairead ^a   Ruppen, Mark ^a   Mansour, Tarek S ^a   Gibbons, James J ^a   Yu, Ker ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 HYDROXYWORTMANIN DERIVATIVE RAPAMYCIN CONJUGATE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG DESIGN; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG MIXTURE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER MICROSOME; MOUSE; NONHUMAN; RAT; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG STABILITY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; MOLECULAR CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RATS; SIROLIMUS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 74849124330     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901427g     Document Type: Article

References (28)

1. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; Kovacevic, Z.; Lesovoy, V.; Schmidt-Wolf, I. G. H.; Barbarash, O.; Gokmen, E.; O'Toole, T.; Lustgarten, S.; Moore, L.; Motzer, R. J. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 2007, 356, 2271-2281.
2. Motzer, R. J.; Escudier, B.; Oudard, S.; Hutson, T. E.; Porta, C.; Bracarda, S.; Grunwald, V.; Thompson, J. A.; Figlin, R. A.; Hollaender, N.; Urbanowitz, G.; Berg, W. J.; Kay, A.; Lebwohl, D.; Ravaud, A. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet 2008, 372, 449-456.
3. Carracedo, A.; Pandolfi, P. P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27, 5527-5541.
4. Guertin, D. A.; Sabatini, D. M. The pharmacology of mTOR inhibition. Sci. Signaling 2009, 2, No. pe24.
5. Meric-Bernstam, F.; Gonzalez-Angulo, A. M. Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 2009, 27, 2278-2287.
6. Sun, S.-Y.; Rosenberg, L. M.; Wang, X.; Zhou, Z.; Yue, P.; Fu, H.; Khuri, F. R. Activation of Akt and elF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65, 7052-7058.
7. Shi, Y.; Yan, H.; Frost, P.; Gera, J.; Lichtenstein, A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther. 2005, 4, 1533-1540.
8. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4 H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 1994, 269, 5241-5248.
9. Norman, B. H.; Shih, C.; Toth, J. E.; Ray, J. E.; Dodge, J. A.; Johnson, D. W.; Rutherford, P. G.; Schulz, R. M.; Worzalla, J. F.; Vlahos, C. J. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J. Med. Chem. 1996, 39, 1106-1111.
10. Wang, X.; Yue, P.; Kim, Y. A.; Fu, H.; Khuri, F. R.; Sun, S.-Y. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res. 2008, 68, 7409-7418.
11. O'Reilly, K. E.; Rojo, F.; She, Q.-B.; Solit, D.; Mills, G. B.; Smith, D.; Lane, H.; Hofmann, F.; Hicklin, D. J.; Ludwig, D. L.; Baselga, J.; Rosen, N. mTORinhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66, 1500-1508.
12. Cloughesy, T. F.; Yoshimoto, K.; Nghiemphu, P.; Brown, K.; Dang, J.; Zhu, S.; Hseuh, T.; Chen, Y.; Wang, W.; Youngkin, D.; Liau, L.; Martin, N.; Becker, D.; Bergsneider, M.; Lai, A.; Green, R.; Oglesby, T.; Koleto, M.; Trent, J.; Horvath, S.; Mischel, P. S.; Mellinghoff, I. K.; Sawyers, C. L. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PloS Med. 2008, 5, 139-151.
13. Yu, K.; Lucas, J.; Zhu, T.; Zask, A.; Gaydos, C.; Toral-Barzar, L.; Gu, J.; Li, F.; Chaudhary, I.; Cai, P.; Lotvin, J.; Petersen, R.; Ruppen, M.; Fawzi, M.; Ayral-Kaloustian, S.; Skotnicki, J.; Mansour, T.; Frost, P.; Gibbons, J. PWT-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase signaling and suppresses growth of solid tumors. Cancer Biol. Ther. 2005, 4, 538-545.
14. Ihle, N. T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M. I.; Paine-Murrieta, G.; Minion, D. J.; Halter, R. J.; Wipf, P.; Abraham, R.; Kirkpatrick, L.; Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 2004, 1535-7163.
15. Wipf, P.; Minion, D. J.; Halter, R. J.; Berggren, M. I.; Ho, C. B.; Chiang, G. G.; Kirkpatrick, L.; Abraham, R.; Powls, G. Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin. Org. Biomol. Chem. 2004, 2, 1911-1920.
16. Zhu, T.; Gu, J.; Yu, K.; Lucas, J.; Cai, P.; Tsao, R.; Gong, Y.; Li, F.; Chaudhary, I.; Desai, P.; Ruppen, M.; Fawzi, M.; Gibbons, J.; Ayral-Kaloustian, S.; Skotnicki, J.; Mansour, T.; Zask, A. Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumor xenograft models. J. Med. Chem. 2006, 49, 1373-1378.
17. Zask, A.; Kaplan, J.; Toral-Barza, L.; Hollander, I.; Young, M.; Tischler, M.; Gaydos, C.; Cinque, M.; Lucas, J.; Yu, K. Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy. J. Med. Chem. 2008, 51, 1319-1323.
18. Eng, C. P.; Sehgal, S. N.; Vezina, C. Activity of rapamycin (AY-22,989) against transplanted tumors. J. Antibiot. 1984, 37, 1231.
19. Goss, R. M.; Lanceron, S. E.; Wise, N. J.; Moss, S. J. Generating rapamycin analogues by directed biosynthesis: starter acid substrate specificity of mono-substituted cyclohexane carboxylic acids. Org. Biomol. Chem. 2006, 4, 4071-4073.
20. Graziani, E. I. Recent advances in the chemistry, biosynthesis and pharmacology of rapamycin analogs. Nat. Prod. Rep. 2009, 26, 602-609.
21. 15
22. Ogawa, Y.; Kodaka, M.; Okuno, H. Trigger lipids inducing pHdependent liposome fusion. Chem. Phys. Lipids 2002, 119, 51-68.
23. Rapamycin 31-trimethylsilyl ether may be synthesized according to the procedure described in the following patent: Shaw, C.-C.; Sellstedt, J.; Noureldin, R.; Cheal, G. K.; Fortier, G. Regioselective Synthesis of Rapamycin Derivatives. U.S. Patent 6,277,983, 2001.
24. Simamora, P.; Alvarez, J. M.; Yalkowsky, S. H. Solubilization of rapamycin. Int. J. Pharm. 2001, 213, 25-29.
25. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6523-6543.
26. Meunier, B. Hybrid molecules with a dual mode of action: dream or reality? Acc. Chem. Res. 2008, 41, 69-77.
27. Findlay, J. A.; Radics, L. On the chemistry and high field nuclear magnetic resonance spectroscopy of rapamycin. Can. J. Chem. 1980, 58, 579-590.
28. Hughes, P.; Musser, J.; Conklin, M.; Russo, R. The isolation, synthesis and characterization of an isomeric form of rapamycin. Tetrahedron Lett. 1992, 33, 4739-4742.